Garo H. Armen - 13 Sep 2021 Form 4 Insider Report for AGENUS INC (AGEN)

Role
Chairman and CEO, Director
Signature
/s/ Garo H. Armen
Issuer symbol
AGEN
Transactions as of
13 Sep 2021
Net transactions value
-$133,257
Form type
4
Filing time
14 Sep 2021, 17:30:36 UTC
Previous filing
21 Jun 2021
Next filing
20 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGEN Common Stock Options Exercise $400,438 +119,178 +16% $3.36 852,880 13 Sep 2021 Direct F1
transaction AGEN Common Stock Sale $533,696 -82,107 -9.6% $6.50 770,773 13 Sep 2021 Direct F4
holding AGEN Common Stock 125,969 13 Sep 2021 See Footnote F2
holding AGEN Common Stock 579,000 13 Sep 2021 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGEN Stock Option, right to buy Options Exercise $0 -119,178 -100% $0.000000* 0 13 Sep 2021 Common Stock 119,178 $3.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.
F2 Shares are held in Dr. Armen's IRA accounts.
F3 Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
F4 Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.